A successful Lygature LIVE 2026: relive the highlights
Thank you to everyone who joined us for Lygature LIVE!
Together, we reflected on 20 years of pioneering partnerships and explored the opportunities shaping the future of health innovation. Watch the aftermovie, read the event report featuring key insights and takeaways, and discover the Lygature 20-year timeline unveiled during the event, showcasing two decades of collaboration and impact.
Watch the aftermovie Read the event report Download timeline PDF
Recent news
-
Lygature LIVE 2026: Two Decades of Collaboration, Looking Ahead to Tomorrow’s Health
On 2 July, Lygature welcomed stakeholders from across academia, industry, patient organizations, and policymaking to its annual event, Lygature LIVE. View the aftermovie and read the full report below. -
Samen bouwen aan betere samenwerking: patiëntparticipatie centraal in PSM
Binnen Patiëntgerichte Samenwerking Medicijnen (PSM) werken patiëntenorganisaties en medicijnbedrijven samen aan één belangrijke ambitie: het patiëntperspectief structureel verankeren in de hele keten van medicijnontwikkeling tot gepast gebruik. Maar waarom is dat zo belangrijk en wat is er nodig om dat in de praktijk te realiseren? -
20 Years of Pioneering Partnerships for Patient Impact: Advancing Global Health
In 2026, Lygature marks 20 years of pioneering partnerships for patient impact. As part of our anniversary year, we are sharing a series of stories highlighting the partnerships, initiatives, and expertise that have shaped our organization and contributed to health innovation over the past two decades.
Our value proposition
Accelerating the development of new medical solutions for patients
Lygature aims to accelerate the development of new medical solutions for patients by driving public-private collaboration between academia, industry and society. We are a not-for-profit organization that enables, drives and supports partnerships to address unmet medical needs.
-
Creating a safe space for innovation
-
Driving the partnership forward to deliver medical solutions
-
Providing specialized support for partnerships
Our projects
-
Regulatory Science Network Netherlands (RSNN)
Joining forces in the Netherlands to promote regulatory science and its application -
CONTRAST 2.0
A multi-stakeholder effort continued from CONTRAST to develop innovative stroke treatments and how logistics of treatment can be improved. -
Non-Biological Complex Drugs (NBCD) Working Group
Towards aligned, science-based approval and post-approval standards for non-biological complex drugs -
ReSToRe
Joining efforts to bring antigen-specific therapy for multiple sclerosis to the clinic -
MOMENTUM
Creating a data repository for tracking outcomes of combining imaging and treatment of common cancer types -
Patient-Focused Medicines Collaboration (PSM)
Strengthening equal and impactful collaboration between patient organisations and pharmaceutical companies -
PREDICTOM
Public private partnership to bring dementia diagnostics closer to the public through a customisable cognitive and biomarker screening platform. -
Pediatric Praziquantel Consortium
Developing and providing a pediatric formulation of the drug praziquantel, to treat schistosomiasis in preschool-aged children -
COREON
Committee and expert network of researchers on Regulation of Health Research -
HPV-kankervrij.nl
Supporting healthcare professionals in eradicating HPV-related cancers. -
BBMRI.nl
Making biosamples, images and data findable, accessible and usable for health research. -
BIGPICTURE
European Digital Pathology Platform for development and validation of Artificial Intelligence -
Centrum voor Proefdiervrij Biomedische Translatie (CPBT)
Animal free biomedical translation for generating safer and more effective treatments. -
FAIRplus
The FAIRplus project aims to develop tools and guidelines for making life science data FAIR -
PERSIST-SEQ
The PERSIST-SEQ project aims to build a reproducible single-cell sequencing workflow to capture tumour persistence -
EPND
Accelerating the discovery of diagnostics and treatment for neurodegenerative diseases by removing barriers to data and sample sharing and fostering collaboration.